Biocartis and Mayo Clinic collaborate
March 2026—Biocartis has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to decrease the time to treatment for breast cancer patients.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Labcorp expands MRD testing
March 2026—Labcorp has expanded its molecular residual disease portfolio to include Labcorp Plasma Detect ID, a whole exome sequence–guided, personalized panel for patients with stages I–III breast cancer or stages I–IIIA non-small cell lung cancer, and Plasma Detect Genome, a whole genome MRD test for stage III colon cancer.
IDT unveils NGS portfolio
March 2026—Integrated DNA Technologies is releasing a suite of next-generation sequencing products that aim to tackle bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
ARUP creates innovation central laboratory
March 2026—ARUP Laboratories has launched an innovation central laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Henry Schein, CytoChip enter distribution agreement
March 2026—Henry Schein entered into an exclusive distribution agreement with CytoChip for CitoCBC, a 510(k)-cleared, CLIA-waived, cartridge-based CBC system. CitoCBC uses blood collected in a venous draw tube to analyze 16 parameters, including the five-part differential. Test results are available in eight minutes.
BD launches urine collection system
March 2026—BD launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system that expands testing capabilities from a single urine specimen.
Fujifilm and Voicebrook partner
February 2026—Fujifilm Healthcare Americas Corp. and Voicebrook are partnering to integrate Voicebrook’s VoiceOver Pro with Fujifilm’s Synapse Pathology, a picture archiving and communication system designed to streamline case management.
BD launches new FacsDiscover A8 configurations
February 2026—BD released new configurations of its FacsDiscover A8 cell analyzers.
Octave, Quest expand access to Octave MSDA test
February 2026—Octave Bioscience is collaborating with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity test accessible through Quest’s nationwide specimen-collection network.
Natera acquires Foresight Dx
February 2026—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics.